This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boehringer Ingelheim Pharmaceuticals.
Reference
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis. Diabetes Therapy : 8 Nov 2021. Available from: URL: https://doi.org/10.1007/s13300-021-01173-0
Rights and permissions
About this article
Cite this article
Empagliflozin less costly than other branded AHAs for T2DM patients with CVD in the USA. PharmacoEcon Outcomes News 891, 11 (2021). https://doi.org/10.1007/s40274-021-08169-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08169-9